How will liquid biopsy change cancer care?
More information on: https://www.i-micronews.com/category-listing/product/liquid-biopsy-from-isolation-to-downstream-applications-2018.html
Cancer Diagnostics Reference Laboratory / NeoGenomics April 2014 investors company overview presentation. This presentation highlights the following:
--Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hostpitals
--Strategic client partnerships created by "Tech-Only" model
--Dynamic, rapidly-growing and consolidating industry
Industry-leading revenue & test volume growth
--Strong productivity and operating leverage leading to accelerating cash flow and net income
--Strong Management Team with large cap lab experience
Global liquid biopsy market opportunity & technology outlook 2020Rajesh Sarma
Global Liquid Biopsy Market Opportunity & Technology Outlook 2020 provides an overview of the liquid biopsy market. Liquid biopsy is a non-invasive method that analyzes blood or other bodily fluids to detect biomarkers associated with cancer and other diseases. It has three main techniques - analysis of circulating tumor cells, cell-free tumor DNA, and exosomes. Next generation sequencing is also used to analyze genomic and proteomic sequences from tumor cells captured in liquid biopsies. The report examines the clinical uses and advantages of liquid biopsy compared to traditional tissue biopsy for various cancer types and other indications. It also discusses market drivers and trends, as well as challenges, for the growing liquid biopsy industry.
This document discusses innovation in clinical laboratory medicine in France and immunology. It notes that historically, university hospital professors were expected to excel in teaching, medical duties, and research to quickly transfer innovations from research to patient care. However, recent regulations and cost-cutting have made this triple mission difficult by increasing administrative burdens and prioritizing reducing healthcare costs over quality. This threatens clinical research initiatives by medical laboratory scientists and reduces training opportunities for future professionals. Nonetheless, there is hope in increasing public awareness of the importance of laboratory medicine and engaging in networking and knowledge-sharing to support innovation.
TexRAD is software that analyzes textures in existing medical scans to provide prognostic information and risk stratification to clinicians. It does this by measuring fine, medium, and coarse textures in scans of tumors like those in the liver, lungs, and other organs. This additional texture information can help predict factors like cancer stage, metastasis risk, and prognosis. TexRAD requires no new scanning procedures and can analyze routine clinical images, providing more information to clinicians to guide patient care decisions.
HDx™ Reference Standards and Reference Materials for Next Generation Sequenci...Candy Smellie
This document summarizes a presentation about reference standards for next generation sequencing (NGS). Horizon Diagnostics has developed genomic DNA and formalin-fixed, paraffin-embedded (FFPE) reference standards containing defined mutations at known allelic frequencies to validate NGS workflows and monitor assay performance. Multiplex reference standards contain up to 40 mutations at low allelic frequencies down to 1.3% that can be quantified using digital PCR. Several laboratories demonstrated they could accurately detect the mutations in Horizon's reference standards using different NGS platforms. The standards help evaluate sensitivity, specificity, and limits of detection on NGS assays.
Certis OncologySolutions provides pre-clinical cancer research services using a technique called Patient-Derived Orthotopic Xenograft (PDOX) mouse modeling. They have an expanding tumor bank with over 300 patient tumors and drug response data. Their facilities include a 7,000 square foot facility in San Diego with lab space. Their unique PDOX model implants patient tumor samples into mice in the same anatomical site as the original tumor to provide a more clinically relevant model for testing drug therapies. Recent studies have shown their PDOX models accurately mimic patient responses to therapies. They offer guidance on pre-clinical studies, execution of drug screening, and publishing assistance to support cancer research.
Certis Oncology | Pre-Clinical Research OfferingsArthurHolmes2
Certis Oncology Solutions provides pre-clinical oncology research services using Patient-Derived Orthotopic Xenograft (PDOX) mouse models. They have expanded their facilities and tumor bank. PDOX models more accurately reflect human cancer compared to traditional PDX models by implanting tumors in their original sites. Certis has affiliations with physicians to obtain tumors and drug response data. They have established over 300 PDOX models representing various cancer types. Certis offers drug screening and individualized treatment data to support cancer research and drug development. They have published several studies demonstrating the clinical relevance and predictive power of their PDOX models.
Cancer Diagnostics Reference Laboratory / NeoGenomics April 2014 investors company overview presentation. This presentation highlights the following:
--Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hostpitals
--Strategic client partnerships created by "Tech-Only" model
--Dynamic, rapidly-growing and consolidating industry
Industry-leading revenue & test volume growth
--Strong productivity and operating leverage leading to accelerating cash flow and net income
--Strong Management Team with large cap lab experience
Global liquid biopsy market opportunity & technology outlook 2020Rajesh Sarma
Global Liquid Biopsy Market Opportunity & Technology Outlook 2020 provides an overview of the liquid biopsy market. Liquid biopsy is a non-invasive method that analyzes blood or other bodily fluids to detect biomarkers associated with cancer and other diseases. It has three main techniques - analysis of circulating tumor cells, cell-free tumor DNA, and exosomes. Next generation sequencing is also used to analyze genomic and proteomic sequences from tumor cells captured in liquid biopsies. The report examines the clinical uses and advantages of liquid biopsy compared to traditional tissue biopsy for various cancer types and other indications. It also discusses market drivers and trends, as well as challenges, for the growing liquid biopsy industry.
This document discusses innovation in clinical laboratory medicine in France and immunology. It notes that historically, university hospital professors were expected to excel in teaching, medical duties, and research to quickly transfer innovations from research to patient care. However, recent regulations and cost-cutting have made this triple mission difficult by increasing administrative burdens and prioritizing reducing healthcare costs over quality. This threatens clinical research initiatives by medical laboratory scientists and reduces training opportunities for future professionals. Nonetheless, there is hope in increasing public awareness of the importance of laboratory medicine and engaging in networking and knowledge-sharing to support innovation.
TexRAD is software that analyzes textures in existing medical scans to provide prognostic information and risk stratification to clinicians. It does this by measuring fine, medium, and coarse textures in scans of tumors like those in the liver, lungs, and other organs. This additional texture information can help predict factors like cancer stage, metastasis risk, and prognosis. TexRAD requires no new scanning procedures and can analyze routine clinical images, providing more information to clinicians to guide patient care decisions.
HDx™ Reference Standards and Reference Materials for Next Generation Sequenci...Candy Smellie
This document summarizes a presentation about reference standards for next generation sequencing (NGS). Horizon Diagnostics has developed genomic DNA and formalin-fixed, paraffin-embedded (FFPE) reference standards containing defined mutations at known allelic frequencies to validate NGS workflows and monitor assay performance. Multiplex reference standards contain up to 40 mutations at low allelic frequencies down to 1.3% that can be quantified using digital PCR. Several laboratories demonstrated they could accurately detect the mutations in Horizon's reference standards using different NGS platforms. The standards help evaluate sensitivity, specificity, and limits of detection on NGS assays.
Certis OncologySolutions provides pre-clinical cancer research services using a technique called Patient-Derived Orthotopic Xenograft (PDOX) mouse modeling. They have an expanding tumor bank with over 300 patient tumors and drug response data. Their facilities include a 7,000 square foot facility in San Diego with lab space. Their unique PDOX model implants patient tumor samples into mice in the same anatomical site as the original tumor to provide a more clinically relevant model for testing drug therapies. Recent studies have shown their PDOX models accurately mimic patient responses to therapies. They offer guidance on pre-clinical studies, execution of drug screening, and publishing assistance to support cancer research.
Certis Oncology | Pre-Clinical Research OfferingsArthurHolmes2
Certis Oncology Solutions provides pre-clinical oncology research services using Patient-Derived Orthotopic Xenograft (PDOX) mouse models. They have expanded their facilities and tumor bank. PDOX models more accurately reflect human cancer compared to traditional PDX models by implanting tumors in their original sites. Certis has affiliations with physicians to obtain tumors and drug response data. They have established over 300 PDOX models representing various cancer types. Certis offers drug screening and individualized treatment data to support cancer research and drug development. They have published several studies demonstrating the clinical relevance and predictive power of their PDOX models.
TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.
Acibadem City Clinic Cancer Center is a modern specialized medical facility for cancer patients. The structure comprises of departments and clinics in Medical oncology, Radiation Oncology, Nuclear Medicine, Radiology and Imaging Diagnostics, Gastroenterology and Clinical Pathology. Chemotherapy, targeted therapy, rehabilitation and psychological support for the patients and their families. Patients have access to cutting-edge technologies such as PET / CT and SPECT / CT imaging, 3D mammography with tomosintesis, robot for automated mixing of medicines and many others. The leading specialists in the hospital are reknown and certified in famous clinics in Europe and around the world.
Flow cytometry in translational cancer research: believe in rare!Marica Gemei
Flow cytometry allows for multiparametric analysis of solid tumors and identification of cancer stem cell markers. The study found that CD66c is upregulated in colon cancer tissues and cancer stem cells, and its expression increases with tumor progression and metastasis. CD66c promotes cancer cell proliferation, survival, and tumorigenic potential. Multiparametric flow cytometry can also identify circulating tumor cells in blood, and detection of CD26+/CD326- CTCs predicts reduced progression-free survival in colon cancer patients.
This document provides a status update and overview of the International Cancer Genomics Consortium (ICGC). The ICGC aims to sequence 500 tumor/normal pairs from 50 different cancer types to identify genome changes and make the data available for research. It coordinates cancer genome projects internationally to maximize data collection while minimizing duplication of efforts. The ICGC has established policies for data access, publication, and intellectual property. To date it has sequenced over 12,000 cancer genomes through 55 projects across 18 jurisdictions. The ICGC Data Coordination Center manages data submission and access and provides portals and tools for searching and accessing datasets.
Global cancer stem cell therapy market outlook 2020KuicK Research
“Global Cancer Stem Cell Therapy Market Outlook 2020” Report Highlight:
Introduction & Classification of Stem Cells
Stem Cell Transplants Classification
Cancer Stem Cell Therapy Mechanism of Action
Global Cancer Stem Cell Market Analysis
Global Cancer Stem Cell Clinical Pipeline by Company & Phase
Global Cancer Stem Cell Clinical Pipeline: 32 Therapies
Global Cancer Stem Cell Market Dynamics: Challenges & Favorable Parameters
Global Cancer Stem Cell Market Future Outlook
Kidney Cancer (Renal Cell Cancer) Global Clinical Trials Review, H2, 2012ReportsnReports
This document provides a 139-page report on global clinical trials for kidney cancer (renal cell cancer) in the second half of 2012. It includes data on the number and location of clinical trials, breakdown of trials by phase, status, subject recruitment, and leading sponsors. The report aims to give an overview of the clinical trial landscape and assess trends in research and development for treating kidney cancer worldwide.
Genomics 2015 Keynote - Utilizing cancer sequencing in the clinicAndreas Scherer
Dr. Andreas Scherer discussed Golden Helix's bioinformatics tools and pipelines for analyzing cancer sequencing data. Golden Helix has over 20 years of experience in developing software for variant analysis, annotation, and reporting. Their tools can align sequencing reads, call variants, annotate variants with public databases, perform tumor-normal comparisons to identify somatic mutations, and generate clinical reports on pathogenic variants relevant for cancer treatment. Dr. Scherer emphasized the challenges of variant annotation and described Golden Helix's extensive variant databases and customization options to support clinical cancer sequencing workflows.
Target discovery is important to reduce drug attrition rates. AstraZeneca uses various target discovery platforms including CRISPR screening to identify novel targets. An example project used CRISPR libraries in prostate cancer cell lines to identify new regulators of androgen receptor stability, which could provide novel treatment targets for castrate resistant prostate cancer.
Targeted nanoparticle tumor ablation. Multi-walled Carbon Nanotubes (MWCNT) are designed with internal antennae tuned to a specific Near Infrared (NIR) laser frequency, which when activated, oscillate at high speeds, generating thermal energy (heat) sufficient to cause cell apoptosis. Using targeting probes, the MWCNT only seek out, attach to, and within, specific cancer cells. The NIR laser is non-invasive, and does not injure the skin. The MWCNT can also be conjugated with probes for very specific imaging for diagnostics purposes using existing MRI technology.
2013 US Tumor Marker Testing Market: Opportunities and Strategies for SupplierReportsnReports
This 620-page report provides a comprehensive analysis of the US tumor marker testing market, including cancer statistics, current and emerging diagnostic tests, instrumentation technologies, test volume and sales forecasts through 2023 for various market segments. It highlights major opportunities for suppliers in reagent kits, instrumentation, automation, and software. The report profiles current and emerging suppliers and provides strategic recommendations to support business strategies.
This document discusses target druggability and efficacy, which are two important components of drug development. It notes that for a target to be druggable, it needs to contain a site that can bind a drug-like molecule, and binding a specific drug needs to modulate the disease process. It then discusses historical drug targets like G protein-coupled receptors, ion channels, nuclear receptors, and protein kinases that have been frequently targeted by drugs. The document examines the types of drugs that were approved in 2013 and the classes of targets they modulated. It analyzes trends in drug innovation and development. Finally, it discusses using genetics and Mendelian randomization to validate drug targets and assess efficacy.
This document discusses next-generation sequencing and its applications in genomics and pathology. It begins with an overview of common NGS terms and technologies. It then covers the typical NGS analysis workflow including quality control, mapping reads to a reference genome, variant calling and annotation. Challenges such as data storage, sharing and reporting are also addressed. The document concludes that clinical sequencing is becoming established but requires ongoing collaboration between pathologists, geneticists and bioinformaticians to realize its potential.
Opportunities in interventional oncology by henry wangaKesho Conference
This document discusses opportunities in interventional oncology. It provides information on various interventional radiology procedures for cancer including angiography, biopsy, drainage, tumor ablation, brachytherapy delivery, embolotherapy, and local delivery of chemotherapy. Examples of treatments used in local hospitals are discussed such as TAE, TACE, and ethanol ablation for liver cancer. Ratings and comments are provided on treatment options for different cases of hepatocellular carcinoma and metastatic liver disease.
Targeted nanoparticle tumor ablation. Multi-walled Carbon Nanotubes (MWCNT) are designed with internal antennae tuned to a specific Near Infrared (NIR) laser frequency, which when activated, oscillate at high speeds, generating thermal energy (heat) sufficient to cause cell apoptosis. Using targeting probes, the MWCNT only seek out, attach to, and within, specific cancer cells. The NIR laser is non-invasive, and does not injure the skin. The MWCNT can also be conjugated with probes for very specific imaging for diagnostics purposes using existing MRI technology.
This document discusses cellular biomarkers for predicting outcomes in lung cancer. It finds that patients with non-small cell lung cancer have elevated levels of circulating endothelial progenitor cells and hematopoietic progenitor cells compared to healthy controls. Surgical removal of the primary tumor normalized these cellular biomarkers, indicating they may be associated with tumor-related angiogenesis and relapse risk. Measuring these cellular biomarkers has potential for predicting prognosis and monitoring response to treatment in lung cancer patients.
OncoPrime - Drug screening platform using patient derived cells Rachna Goyal
OncoPrime is Saarum Sciences platform utilizing patient derived cells in various culture formats, phenotypes and genotypes for drug screening assays. Key advantage is testing your compounds/ molecules against the DIVERSITY that will be met in Clinics !!
Additional value of prenatal genomic array testing in fetuses with isolated structural ultrasound abnormalities and a normal karyotype: a systematic review of the literature
M.C. de Wit, M.I. Srebniak, L.C.P. Govaerts, D. Van Opstal, R.J.H. Galjaard and A.T.J.I. Go
Link to free access article: http://onlinelibrary.wiley.com/doi/10.1002/uog.12575/abstract
Artificial Organ Technology and Market Analysis 2017 Report by Yole Developpe...Yole Developpement
How will artificial organs revolutionize organ transplants and overcome shortages in the next 20 years?
FIVE OUT OF THE TEN LEADING CAUSES OF DEATH IN THE WORLD WILL BENEFIT FROM ARTIFICIAL ORGANS
Organ transplantation is often the only treatment for end-state organ failure, such as liver, kidney and heart failure. Tragically, most people on the waiting list die before they ever get an organ. Hence the dream of developing artificial organs made of electronic and mechanical parts has been around for decades. The first total artificial heart transplant was in the 1980s, yet since then few improvements have made these devices more efficient. Newcomers such as Carmat and Bivacor are aiming to change the paradigm from a single mechanical heart towards a smarter solution, with embedded sensors and intelligence.
The next wave of development came from the diabetes epidemic that affects every country, hitting more than 8% of the global population today. The artificial pancreas market will therefore experience a huge 49% compound annual growth rate (CAGR) over the next five years, to reach $1.3B in 2022. The next breakthrough to happen will come in 5-10 years, bringing artificial lungs and kidneys. The first commercially approved devices will be wearable systems such as the Wearable Artificial Kidney Foundation, Inc. (WAKFI) system.
More information on that report at http://www.i-micronews.com/reports.html
The document provides an overview of the global liquid biopsy market forecast from 2020 to 2025. It discusses key aspects of the market such as application, end user, clinical application, product/service, circulating biomarker, technology, and region. It also profiles major companies in the market and their recent developments. The global liquid biopsy market is expected to grow significantly due to the rising adoption of non-invasive cancer screening and monitoring techniques. However, lack of standardization and low reimbursement rates may hinder the market growth.
TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.
Acibadem City Clinic Cancer Center is a modern specialized medical facility for cancer patients. The structure comprises of departments and clinics in Medical oncology, Radiation Oncology, Nuclear Medicine, Radiology and Imaging Diagnostics, Gastroenterology and Clinical Pathology. Chemotherapy, targeted therapy, rehabilitation and psychological support for the patients and their families. Patients have access to cutting-edge technologies such as PET / CT and SPECT / CT imaging, 3D mammography with tomosintesis, robot for automated mixing of medicines and many others. The leading specialists in the hospital are reknown and certified in famous clinics in Europe and around the world.
Flow cytometry in translational cancer research: believe in rare!Marica Gemei
Flow cytometry allows for multiparametric analysis of solid tumors and identification of cancer stem cell markers. The study found that CD66c is upregulated in colon cancer tissues and cancer stem cells, and its expression increases with tumor progression and metastasis. CD66c promotes cancer cell proliferation, survival, and tumorigenic potential. Multiparametric flow cytometry can also identify circulating tumor cells in blood, and detection of CD26+/CD326- CTCs predicts reduced progression-free survival in colon cancer patients.
This document provides a status update and overview of the International Cancer Genomics Consortium (ICGC). The ICGC aims to sequence 500 tumor/normal pairs from 50 different cancer types to identify genome changes and make the data available for research. It coordinates cancer genome projects internationally to maximize data collection while minimizing duplication of efforts. The ICGC has established policies for data access, publication, and intellectual property. To date it has sequenced over 12,000 cancer genomes through 55 projects across 18 jurisdictions. The ICGC Data Coordination Center manages data submission and access and provides portals and tools for searching and accessing datasets.
Global cancer stem cell therapy market outlook 2020KuicK Research
“Global Cancer Stem Cell Therapy Market Outlook 2020” Report Highlight:
Introduction & Classification of Stem Cells
Stem Cell Transplants Classification
Cancer Stem Cell Therapy Mechanism of Action
Global Cancer Stem Cell Market Analysis
Global Cancer Stem Cell Clinical Pipeline by Company & Phase
Global Cancer Stem Cell Clinical Pipeline: 32 Therapies
Global Cancer Stem Cell Market Dynamics: Challenges & Favorable Parameters
Global Cancer Stem Cell Market Future Outlook
Kidney Cancer (Renal Cell Cancer) Global Clinical Trials Review, H2, 2012ReportsnReports
This document provides a 139-page report on global clinical trials for kidney cancer (renal cell cancer) in the second half of 2012. It includes data on the number and location of clinical trials, breakdown of trials by phase, status, subject recruitment, and leading sponsors. The report aims to give an overview of the clinical trial landscape and assess trends in research and development for treating kidney cancer worldwide.
Genomics 2015 Keynote - Utilizing cancer sequencing in the clinicAndreas Scherer
Dr. Andreas Scherer discussed Golden Helix's bioinformatics tools and pipelines for analyzing cancer sequencing data. Golden Helix has over 20 years of experience in developing software for variant analysis, annotation, and reporting. Their tools can align sequencing reads, call variants, annotate variants with public databases, perform tumor-normal comparisons to identify somatic mutations, and generate clinical reports on pathogenic variants relevant for cancer treatment. Dr. Scherer emphasized the challenges of variant annotation and described Golden Helix's extensive variant databases and customization options to support clinical cancer sequencing workflows.
Target discovery is important to reduce drug attrition rates. AstraZeneca uses various target discovery platforms including CRISPR screening to identify novel targets. An example project used CRISPR libraries in prostate cancer cell lines to identify new regulators of androgen receptor stability, which could provide novel treatment targets for castrate resistant prostate cancer.
Targeted nanoparticle tumor ablation. Multi-walled Carbon Nanotubes (MWCNT) are designed with internal antennae tuned to a specific Near Infrared (NIR) laser frequency, which when activated, oscillate at high speeds, generating thermal energy (heat) sufficient to cause cell apoptosis. Using targeting probes, the MWCNT only seek out, attach to, and within, specific cancer cells. The NIR laser is non-invasive, and does not injure the skin. The MWCNT can also be conjugated with probes for very specific imaging for diagnostics purposes using existing MRI technology.
2013 US Tumor Marker Testing Market: Opportunities and Strategies for SupplierReportsnReports
This 620-page report provides a comprehensive analysis of the US tumor marker testing market, including cancer statistics, current and emerging diagnostic tests, instrumentation technologies, test volume and sales forecasts through 2023 for various market segments. It highlights major opportunities for suppliers in reagent kits, instrumentation, automation, and software. The report profiles current and emerging suppliers and provides strategic recommendations to support business strategies.
This document discusses target druggability and efficacy, which are two important components of drug development. It notes that for a target to be druggable, it needs to contain a site that can bind a drug-like molecule, and binding a specific drug needs to modulate the disease process. It then discusses historical drug targets like G protein-coupled receptors, ion channels, nuclear receptors, and protein kinases that have been frequently targeted by drugs. The document examines the types of drugs that were approved in 2013 and the classes of targets they modulated. It analyzes trends in drug innovation and development. Finally, it discusses using genetics and Mendelian randomization to validate drug targets and assess efficacy.
This document discusses next-generation sequencing and its applications in genomics and pathology. It begins with an overview of common NGS terms and technologies. It then covers the typical NGS analysis workflow including quality control, mapping reads to a reference genome, variant calling and annotation. Challenges such as data storage, sharing and reporting are also addressed. The document concludes that clinical sequencing is becoming established but requires ongoing collaboration between pathologists, geneticists and bioinformaticians to realize its potential.
Opportunities in interventional oncology by henry wangaKesho Conference
This document discusses opportunities in interventional oncology. It provides information on various interventional radiology procedures for cancer including angiography, biopsy, drainage, tumor ablation, brachytherapy delivery, embolotherapy, and local delivery of chemotherapy. Examples of treatments used in local hospitals are discussed such as TAE, TACE, and ethanol ablation for liver cancer. Ratings and comments are provided on treatment options for different cases of hepatocellular carcinoma and metastatic liver disease.
Targeted nanoparticle tumor ablation. Multi-walled Carbon Nanotubes (MWCNT) are designed with internal antennae tuned to a specific Near Infrared (NIR) laser frequency, which when activated, oscillate at high speeds, generating thermal energy (heat) sufficient to cause cell apoptosis. Using targeting probes, the MWCNT only seek out, attach to, and within, specific cancer cells. The NIR laser is non-invasive, and does not injure the skin. The MWCNT can also be conjugated with probes for very specific imaging for diagnostics purposes using existing MRI technology.
This document discusses cellular biomarkers for predicting outcomes in lung cancer. It finds that patients with non-small cell lung cancer have elevated levels of circulating endothelial progenitor cells and hematopoietic progenitor cells compared to healthy controls. Surgical removal of the primary tumor normalized these cellular biomarkers, indicating they may be associated with tumor-related angiogenesis and relapse risk. Measuring these cellular biomarkers has potential for predicting prognosis and monitoring response to treatment in lung cancer patients.
OncoPrime - Drug screening platform using patient derived cells Rachna Goyal
OncoPrime is Saarum Sciences platform utilizing patient derived cells in various culture formats, phenotypes and genotypes for drug screening assays. Key advantage is testing your compounds/ molecules against the DIVERSITY that will be met in Clinics !!
Additional value of prenatal genomic array testing in fetuses with isolated structural ultrasound abnormalities and a normal karyotype: a systematic review of the literature
M.C. de Wit, M.I. Srebniak, L.C.P. Govaerts, D. Van Opstal, R.J.H. Galjaard and A.T.J.I. Go
Link to free access article: http://onlinelibrary.wiley.com/doi/10.1002/uog.12575/abstract
Artificial Organ Technology and Market Analysis 2017 Report by Yole Developpe...Yole Developpement
How will artificial organs revolutionize organ transplants and overcome shortages in the next 20 years?
FIVE OUT OF THE TEN LEADING CAUSES OF DEATH IN THE WORLD WILL BENEFIT FROM ARTIFICIAL ORGANS
Organ transplantation is often the only treatment for end-state organ failure, such as liver, kidney and heart failure. Tragically, most people on the waiting list die before they ever get an organ. Hence the dream of developing artificial organs made of electronic and mechanical parts has been around for decades. The first total artificial heart transplant was in the 1980s, yet since then few improvements have made these devices more efficient. Newcomers such as Carmat and Bivacor are aiming to change the paradigm from a single mechanical heart towards a smarter solution, with embedded sensors and intelligence.
The next wave of development came from the diabetes epidemic that affects every country, hitting more than 8% of the global population today. The artificial pancreas market will therefore experience a huge 49% compound annual growth rate (CAGR) over the next five years, to reach $1.3B in 2022. The next breakthrough to happen will come in 5-10 years, bringing artificial lungs and kidneys. The first commercially approved devices will be wearable systems such as the Wearable Artificial Kidney Foundation, Inc. (WAKFI) system.
More information on that report at http://www.i-micronews.com/reports.html
The document provides an overview of the global liquid biopsy market forecast from 2020 to 2025. It discusses key aspects of the market such as application, end user, clinical application, product/service, circulating biomarker, technology, and region. It also profiles major companies in the market and their recent developments. The global liquid biopsy market is expected to grow significantly due to the rising adoption of non-invasive cancer screening and monitoring techniques. However, lack of standardization and low reimbursement rates may hinder the market growth.
Currently worth a few million dollars, the emerging organs-on-chips market has the potential to become a multi-billion dollar market.
Organs-on-chips: the promise of solving one of the pharmaceutical industry’s major hurdles
Bringing a new drug to market is one of the longest and most costly paths any industry has to walk. Companies start with several thousands of compounds that may have positive effects against a disease or a human condition. More than twelve years and several billion dollars later, if they’re lucky they managed to get one of these compounds onto the market. All the others failed at one stage or another during the drug development process – and the later the failure, the more expensive it is. Current methods – cell culture in petri dishes and animal testing among others – are not predictive enough. Around 90% of drugs that have been validated on these models then fail during clinical trials because of toxicity or lack of efficacy. The pharmaceutical industry therefore needs more predictive tools to make drug candidates fail earlier and cheaper. Other industries where toxicity testing is a major concern, such as cosmetics, agro-food and consumer goods, also need such solutions, in particular because animal testing is now banned for these industries in certain geographical areas. Several options have been envisioned, the most promising of which is certainly organs-on-chips. These combinations of micro-technology and biology reconstitute the physiological and mechanical functions of human organs under the form of micro-engineered devices lined with living cells. Precisely controlled fluid flows combined with mechanical cues and tissue-tissue interfaces enable dynamic models, much more relevant than conventional static cell cultures. As a sign of confidence in this technology, significant funding has been allocated to organs-on-chips developers: DARPA and the NIH respectively awarded $140M and $76M over 5-year periods to support developments. In parallel, technology developers have raised more than $80M since 2012 with investors. In Yole Développement’s report, all the key elements to understand the organs-on-chips landscape are detailed.
For more information, please visit our website: https://www.i-micronews.com/reports.html
Cell-Based Assay Market 2022-2027: Size, Share, Trends, Analysis & Research ...IMARC Group
According to the latest report by IMARC Group, that the global cell-based assay market size reached US$ 18.9 Billion in 2021. Cell-based assay or cellular assay is an analytical method to determine the concentration of a substance by observing its effects on living organisms (in vivo) or tissues (in vitro). It provides a closer representation of the real-life model, which helps to verify the biological activity of drugs and determine whether the antibodies produced by the patient are neutralizing the drug.
Blood Culture Test Market PPT: Demand, Trends and Business Opportunities 2023-28IMARC Group
The global blood culture test market size reached US$ 4.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 7.7 Billion by 2028, exhibiting a growth rate (CAGR) of 8.5% during 2023-2028.
More Info:- https://www.imarcgroup.com/blood-culture-test-market
The investor presentation discusses Cancer Genetics, Inc., a company that provides genomic testing services. It highlights the company's recent growth, including acquisitions, research collaborations, product launches, and patents. The presentation also outlines the company's targeted NGS panel pipeline for diseases like multiple myeloma, CLL, and myeloid cancers. It positions Cancer Genetics as a leader in oncology diagnostics with proprietary tests that can help guide cancer diagnosis, prognosis, and treatment selection.
The document discusses Strand Genomics Inc., which offers genomic analysis and clinical interpretation software and services. It focuses on personalized medicine by using its StrandOmics platform to analyze genomic data and determine disease risks for individuals. StrandOmics aims to make genomic testing routine in medical care to help clinicians make more informed decisions. Strand has grown to over 200 scientists and serves over 2,000 labs and 100,000 patients. Its partnership with Health Care Global Enterprises successfully piloted cancer risk assessment and molecular diagnosis for over 50 patients in India.
5 Cutting-Edge Trends in Molecular DiagnosticsBruce Carlson
Despite the focus on novelty in this field, it is near 2 decades old. Yet a lot is changing. A look at a few trends that could change molecular diagnostics.
Cancer Biomarkers Market by Product Type, Distribution Channel, End User 2024...IMARC Group
The global cancer biomarkers market size reached US$ 27.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 77.0 Billion by 2032, exhibiting a growth rate (CAGR) of 11.7% during 2024-2032.
More Info:- https://www.imarcgroup.com/cancer-biomarkers-market
Cancer Tumor Profiling Market Growth, Demand and Challenges of the Key Indust...IMARC Group
The global cancer tumor profiling market reached a value of US$ 9.38 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 18.22 Billion by 2027 exhibiting a growth rate (CAGR) of 11.20% during 2022-2027.
More Info:- https://www.imarcgroup.com/cancer-tumor-profiling-market
CRISPR Technology & Market Overview: from Lab to Industry 2018 Report by Yol...Yole Developpement
CRISPR-based products in biotech, agritech and diagnostics markets will reach $5B in 2023 before extra growth comes from therapeutic applications.
More information on that report at https://www.i-micronews.com/category-listing/product/crispr-technology-market-overview-from-lab-to-industry-2018.html
Dialysis Market PPT: Demand, Trends and Business Opportunities 2023-28IMARC Group
The global dialysis market size reached US$ 110.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 148.8 Billion by 2028, exhibiting a growth rate (CAGR) of 4.9% during 2023-2028.
More info:- https://www.imarcgroup.com/dialysis-market
Liquid Biopsy Market PPT 2023: Size, Growth, Demand and Forecast till 2028IMARC Group
The global liquid biopsy market size reached US$ 1.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.3 Billion by 2028, exhibiting a growth rate (CAGR) of 15.3% during 2023-2028.
More Info:- https://www.imarcgroup.com/liquid-biopsy-market
The document discusses liquid biopsies and next generation cancer molecular diagnostics. It summarizes that OncoCyte Corporation is focused on developing diagnostic tests for early cancer detection using liquid biopsies, with an initial focus on tests for lung cancer. Key points include that lung cancer diagnostics represents a large market opportunity and that OncoCyte's preliminary lung cancer diagnostic test shows strong performance in clinical trials with high sensitivity and specificity. The test has the potential to reduce risky follow-up procedures for patients and provide significant healthcare cost savings.
This document discusses Biocept, Inc., a commercial-stage cancer diagnostics company. It provides an overview of Biocept's liquid biopsy platform and tests, including OncoCEE-BR, their first commercialized test for breast cancer. The document also summarizes Biocept's growth strategy, which includes expanding their test menu, improving operational efficiency, and increasing market penetration. It introduces Biocept's executive team and describes their extensive experience in cancer diagnostics, genomics, and life sciences.
This document discusses Biocept, Inc., a commercial-stage cancer diagnostics company. It provides an overview of Biocept's liquid biopsy platform and tests, including OncoCEE and OncoCEE-BR, which measure circulating tumor cells. The document highlights Biocept's multi-faceted growth strategy including test menu expansion and increasing operational efficiency. It also introduces Biocept's executive team and discusses the large US market opportunity for cancer diagnostics.
This document discusses Biocept, Inc., a commercial-stage cancer diagnostics company. It provides an overview of Biocept's liquid biopsy platform and tests, including OncoCEE-BR, their first commercialized test for breast cancer. The document also summarizes Biocept's growth strategy, which includes expanding their test menu, improving operational efficiency, and increasing market penetration. It introduces Biocept's executive team and describes their extensive experience in cancer diagnostics, genomics, and life sciences.
The Science of Launching and Achieving Growth in Oncologyaccenture
We have conducted research to understand how oncology companies are responding to New science, more treatment choices and changing economics. Visit https://accntu.re/2Jn72wq to learn our key takeaways for launching and achieving growth in oncology.
Colorectal Cancer Market 2023: Epidemiology, Industry Trends, Size, Share And...frankmorgan27
The increasing occurrences of polyps and inflammatory bowel conditions like ulcerative colitis or Crohn’s disease are primarily propelling the colorectal cancer market.
This document provides information about BioTechPharma (BTP) and its subsidiaries. BTP developed a patented front-end collection and testing platform using nanotechnology and microfluidics. The platform can test samples for metabolites, proteins or biomarkers. BTP seeks to partner with companies and organizations to commercialize its platform. It offers sample collection kits that can detect drugs, hormones, DNA and cancer markers in saliva, urine and other bodily fluids. BTP also provides contract manufacturing and has FDA and government certifications. It aims to be a strategic partner for supply chain and healthcare needs.
Similar to Liquid Biopsy: From Isolation to Downstream Applications 2018 Report by Yole Developpement (20)
Computing and AI technologies for mobile and consumer applications 2021 - SampleYole Developpement
Penetrating everyday products will see the market for AI technologies for the consumer market reach $5.6B in 2026.
More information : https://www.i-micronews.com/products/computing-and-ai-technologies-for-mobile-and-consumer-applications-2021/
For the first time, the processor monitor is including FPGA, CPU, GPU, and APU including all the IDMs, fabless companies, and foundries in the business.
More information : https://www.i-micronews.com/products/application-processor-quarterly-market-monitor/
For the first time in its history, the automotive industry must face new industrial and technological
challenges while undergoing dramatic changes in its value chain.
More information: https://www.i-micronews.com/products/automotive-semiconductor-trends-2021/
MicroLED Displays - Market, Industry and Technology Trends 2021Yole Developpement
Strong momentum for MicroLED with progress on all fronts. Cost is the biggest challenge, but Apple and Samsung are carving paths toward the consumer.
More information; https://www.i-micronews.com/products/microled-displays-market-industry-and-technology-trends-2021/
System-in-Package Technology and Market Trends 2021 - SampleYole Developpement
Through enabling design and supply chain agility, SiP will reach $19B by 2026, with IDMs, OSATs, and foundries taking advantage of it.
More information : https://www.i-micronews.com/products/system-in-package-technology-and-market-trends-2021/
Industrial, consumer, and automotive applications are driving the adoption of neuromorphic computing and sensing technologies. The first products are now hitting the market.
More information: https://www.i-micronews.com/products/neuromorphic-computing-and-sensing-2021/
Beyond communication, silicon photonics is penetrating consumer and automotive – heading to $1.1B in 2026.
More information: https://www.i-micronews.com/products/silicon-photonics-2021/
Semiconductor technologies will enable increased mobility and communication for the soldier of the future. This market will reach $17.5B in 2030+.
More information: https://www.i-micronews.com/products/future-soldier-technologies-2021/
This report from Yole Développement analyzes the high-end performance packaging market. It defines high-end performance packaging as technologies that provide high IO density (≥16/mm2) and fine IO pitch (≤130μm). The report aims to identify relevant technologies, analyze market drivers and challenges, describe technology trends and roadmaps, examine the supply chain landscape, and provide market forecasts. It evaluates the market by technology, end application, and region. The report also profiles key players' technology roadmaps and analyzes intellectual property in the 3D SoC hybrid bonding space.
5G’s Impact on RF Front-End and Connectivity for Cellphones 2020Yole Developpement
An intensifying US-China competition for RF technology supremacy.
More information on: https://www.i-micronews.com/products/5gs-impact-on-rf-front-end-and-connectivity-for-cellphones-2020/
In the ultrasound module market, CMUT and PMUT are growing two times faster in medical and consumer applications.
More information: https://www.i-micronews.com/products/ultrasound-sensing-technologies-2020/
The entrance of Chinese players and the rise of new technical solutions are poised to trigger profound changes in the memory business.
More information on: https://www.i-micronews.com/products/status-of-the-memory-industry-2020/
GaAs Wafer and Epiwafer Market: RF, Photonics, LED, Display and PV Applicatio...Yole Developpement
The report provides a market analysis of the GaAs wafer and epiwafer markets from 2019 to 2025. It forecasts that the GaAs wafer market will increase from $200 million in 2019 to $348 million in 2025, with the largest application segments being RF, photonics, and LED. The open epiwafer market is also analyzed, with IQE and VPEC together comprising almost 80% of the $262 million total market in 2019. Key drivers of growth are discussed for various applications such as 5G adoption for RF and increasing use of VCSELs for 3D sensing and LiDAR.
Status of the Radar Industry: Players, Applications and Technology Trends 2020Yole Developpement
Worth more than $20B in 2019, the radar industry is experiencing a major transformation prior to entering the commercial era.
Learn more about the report here: https://www.i-micronews.com/products/status-of-the-radar-industry-players-applications-and-technology-trends-2020/
GaN RF Market: Applications, Players, Technology and Substrates 2020Yole Developpement
Driven by military applications and 5G telecom infrastructure, the GaN RF market continues growing.
Learn more about the report here: https://www.i-micronews.com/products/gan-rf-market-applications-players-technology-and-substrates-2020/
Pressure, inertial, MEMS ultrasound, microfluidic chips and other sensors are driving the growth of the life sciences and healthcare market.
More information: https://www.i-micronews.com/products/biomems-market-and-technology-2020/
Market will more than double by 2025 driven by heavy investments in data centers.
More information: https://www.i-micronews.com/products/optical-transceivers-for-datacom-telecom-2020/
COVID-19 is shaking up the diagnostics industry and will have both short- and long-term impact.
More information: https://www.i-micronews.com/products/point-of-need-2020-including-pcr-based-testing/
Pluggable transceivers in high volume production. Co-packaged optics in line of sight.
More information on: https://www.i-micronews.com/products/silicon-photonics-2020/
GraphSummit Singapore | The Art of the Possible with Graph - Q2 2024Neo4j
Neha Bajwa, Vice President of Product Marketing, Neo4j
Join us as we explore breakthrough innovations enabled by interconnected data and AI. Discover firsthand how organizations use relationships in data to uncover contextual insights and solve our most pressing challenges – from optimizing supply chains, detecting fraud, and improving customer experiences to accelerating drug discoveries.
Unlock the Future of Search with MongoDB Atlas_ Vector Search Unleashed.pdfMalak Abu Hammad
Discover how MongoDB Atlas and vector search technology can revolutionize your application's search capabilities. This comprehensive presentation covers:
* What is Vector Search?
* Importance and benefits of vector search
* Practical use cases across various industries
* Step-by-step implementation guide
* Live demos with code snippets
* Enhancing LLM capabilities with vector search
* Best practices and optimization strategies
Perfect for developers, AI enthusiasts, and tech leaders. Learn how to leverage MongoDB Atlas to deliver highly relevant, context-aware search results, transforming your data retrieval process. Stay ahead in tech innovation and maximize the potential of your applications.
#MongoDB #VectorSearch #AI #SemanticSearch #TechInnovation #DataScience #LLM #MachineLearning #SearchTechnology
HCL Notes und Domino Lizenzkostenreduzierung in der Welt von DLAUpanagenda
Webinar Recording: https://www.panagenda.com/webinars/hcl-notes-und-domino-lizenzkostenreduzierung-in-der-welt-von-dlau/
DLAU und die Lizenzen nach dem CCB- und CCX-Modell sind für viele in der HCL-Community seit letztem Jahr ein heißes Thema. Als Notes- oder Domino-Kunde haben Sie vielleicht mit unerwartet hohen Benutzerzahlen und Lizenzgebühren zu kämpfen. Sie fragen sich vielleicht, wie diese neue Art der Lizenzierung funktioniert und welchen Nutzen sie Ihnen bringt. Vor allem wollen Sie sicherlich Ihr Budget einhalten und Kosten sparen, wo immer möglich. Das verstehen wir und wir möchten Ihnen dabei helfen!
Wir erklären Ihnen, wie Sie häufige Konfigurationsprobleme lösen können, die dazu führen können, dass mehr Benutzer gezählt werden als nötig, und wie Sie überflüssige oder ungenutzte Konten identifizieren und entfernen können, um Geld zu sparen. Es gibt auch einige Ansätze, die zu unnötigen Ausgaben führen können, z. B. wenn ein Personendokument anstelle eines Mail-Ins für geteilte Mailboxen verwendet wird. Wir zeigen Ihnen solche Fälle und deren Lösungen. Und natürlich erklären wir Ihnen das neue Lizenzmodell.
Nehmen Sie an diesem Webinar teil, bei dem HCL-Ambassador Marc Thomas und Gastredner Franz Walder Ihnen diese neue Welt näherbringen. Es vermittelt Ihnen die Tools und das Know-how, um den Überblick zu bewahren. Sie werden in der Lage sein, Ihre Kosten durch eine optimierte Domino-Konfiguration zu reduzieren und auch in Zukunft gering zu halten.
Diese Themen werden behandelt
- Reduzierung der Lizenzkosten durch Auffinden und Beheben von Fehlkonfigurationen und überflüssigen Konten
- Wie funktionieren CCB- und CCX-Lizenzen wirklich?
- Verstehen des DLAU-Tools und wie man es am besten nutzt
- Tipps für häufige Problembereiche, wie z. B. Team-Postfächer, Funktions-/Testbenutzer usw.
- Praxisbeispiele und Best Practices zum sofortigen Umsetzen
Let's Integrate MuleSoft RPA, COMPOSER, APM with AWS IDP along with Slackshyamraj55
Discover the seamless integration of RPA (Robotic Process Automation), COMPOSER, and APM with AWS IDP enhanced with Slack notifications. Explore how these technologies converge to streamline workflows, optimize performance, and ensure secure access, all while leveraging the power of AWS IDP and real-time communication via Slack notifications.
HCL Notes and Domino License Cost Reduction in the World of DLAUpanagenda
Webinar Recording: https://www.panagenda.com/webinars/hcl-notes-and-domino-license-cost-reduction-in-the-world-of-dlau/
The introduction of DLAU and the CCB & CCX licensing model caused quite a stir in the HCL community. As a Notes and Domino customer, you may have faced challenges with unexpected user counts and license costs. You probably have questions on how this new licensing approach works and how to benefit from it. Most importantly, you likely have budget constraints and want to save money where possible. Don’t worry, we can help with all of this!
We’ll show you how to fix common misconfigurations that cause higher-than-expected user counts, and how to identify accounts which you can deactivate to save money. There are also frequent patterns that can cause unnecessary cost, like using a person document instead of a mail-in for shared mailboxes. We’ll provide examples and solutions for those as well. And naturally we’ll explain the new licensing model.
Join HCL Ambassador Marc Thomas in this webinar with a special guest appearance from Franz Walder. It will give you the tools and know-how to stay on top of what is going on with Domino licensing. You will be able lower your cost through an optimized configuration and keep it low going forward.
These topics will be covered
- Reducing license cost by finding and fixing misconfigurations and superfluous accounts
- How do CCB and CCX licenses really work?
- Understanding the DLAU tool and how to best utilize it
- Tips for common problem areas, like team mailboxes, functional/test users, etc
- Practical examples and best practices to implement right away
Building Production Ready Search Pipelines with Spark and MilvusZilliz
Spark is the widely used ETL tool for processing, indexing and ingesting data to serving stack for search. Milvus is the production-ready open-source vector database. In this talk we will show how to use Spark to process unstructured data to extract vector representations, and push the vectors to Milvus vector database for search serving.
“An Outlook of the Ongoing and Future Relationship between Blockchain Technologies and Process-aware Information Systems.” Invited talk at the joint workshop on Blockchain for Information Systems (BC4IS) and Blockchain for Trusted Data Sharing (B4TDS), co-located with with the 36th International Conference on Advanced Information Systems Engineering (CAiSE), 3 June 2024, Limassol, Cyprus.
Pushing the limits of ePRTC: 100ns holdover for 100 daysAdtran
At WSTS 2024, Alon Stern explored the topic of parametric holdover and explained how recent research findings can be implemented in real-world PNT networks to achieve 100 nanoseconds of accuracy for up to 100 days.
AI 101: An Introduction to the Basics and Impact of Artificial IntelligenceIndexBug
Imagine a world where machines not only perform tasks but also learn, adapt, and make decisions. This is the promise of Artificial Intelligence (AI), a technology that's not just enhancing our lives but revolutionizing entire industries.
Infrastructure Challenges in Scaling RAG with Custom AI modelsZilliz
Building Retrieval-Augmented Generation (RAG) systems with open-source and custom AI models is a complex task. This talk explores the challenges in productionizing RAG systems, including retrieval performance, response synthesis, and evaluation. We’ll discuss how to leverage open-source models like text embeddings, language models, and custom fine-tuned models to enhance RAG performance. Additionally, we’ll cover how BentoML can help orchestrate and scale these AI components efficiently, ensuring seamless deployment and management of RAG systems in the cloud.
UiPath Test Automation using UiPath Test Suite series, part 6DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 6. In this session, we will cover Test Automation with generative AI and Open AI.
UiPath Test Automation with generative AI and Open AI webinar offers an in-depth exploration of leveraging cutting-edge technologies for test automation within the UiPath platform. Attendees will delve into the integration of generative AI, a test automation solution, with Open AI advanced natural language processing capabilities.
Throughout the session, participants will discover how this synergy empowers testers to automate repetitive tasks, enhance testing accuracy, and expedite the software testing life cycle. Topics covered include the seamless integration process, practical use cases, and the benefits of harnessing AI-driven automation for UiPath testing initiatives. By attending this webinar, testers, and automation professionals can gain valuable insights into harnessing the power of AI to optimize their test automation workflows within the UiPath ecosystem, ultimately driving efficiency and quality in software development processes.
What will you get from this session?
1. Insights into integrating generative AI.
2. Understanding how this integration enhances test automation within the UiPath platform
3. Practical demonstrations
4. Exploration of real-world use cases illustrating the benefits of AI-driven test automation for UiPath
Topics covered:
What is generative AI
Test Automation with generative AI and Open AI.
UiPath integration with generative AI
Speaker:
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
Sudheer Mechineni, Head of Application Frameworks, Standard Chartered Bank
Discover how Standard Chartered Bank harnessed the power of Neo4j to transform complex data access challenges into a dynamic, scalable graph database solution. This keynote will cover their journey from initial adoption to deploying a fully automated, enterprise-grade causal cluster, highlighting key strategies for modelling organisational changes and ensuring robust disaster recovery. Learn how these innovations have not only enhanced Standard Chartered Bank’s data infrastructure but also positioned them as pioneers in the banking sector’s adoption of graph technology.
Full-RAG: A modern architecture for hyper-personalizationZilliz
Mike Del Balso, CEO & Co-Founder at Tecton, presents "Full RAG," a novel approach to AI recommendation systems, aiming to push beyond the limitations of traditional models through a deep integration of contextual insights and real-time data, leveraging the Retrieval-Augmented Generation architecture. This talk will outline Full RAG's potential to significantly enhance personalization, address engineering challenges such as data management and model training, and introduce data enrichment with reranking as a key solution. Attendees will gain crucial insights into the importance of hyperpersonalization in AI, the capabilities of Full RAG for advanced personalization, and strategies for managing complex data integrations for deploying cutting-edge AI solutions.
GraphRAG for Life Science to increase LLM accuracyTomaz Bratanic
GraphRAG for life science domain, where you retriever information from biomedical knowledge graphs using LLMs to increase the accuracy and performance of generated answers
3. 3
Biographies & contacts
ABOUT THE AUTHORS
Dr. MarjorieVillien
Sébastien Clerc
• Sébastien Clerc is a Medical Technologies Analyst at Yole Développement, the "More than Moore" market research and strategy consulting company.
After graduating from Grenoble Institute of Technology with a Master’s degree in Biomedical Technologies, he completed his training with a Master’s
of Innovation and Technology Management, during which he oversaw strategy and marketing.
• Email: clerc@yole.fr
• As a Technology & Market Analyst, Dr. Marjorie Villien works in the Microfluidic & Medical Technologies (MedTech) business unit at Yole
Développement, the "More than Moore" market research and strategy consulting company. She is a daily contributor to the development of
MedTech activities, with a dedicated collection of market & technology reports as well as custom consulting projects. After spending two years at
Harvard, Dr. Villien served as a research scientist at INSERM in the field of MRI & PET imaging. She has spoken at numerous international
conferences and has authored or co-authored 11 papers and one patent. Dr. Villien graduated from Grenoble INP and holds a PhD in Physics &
Medical Imaging.
• Email: villien@yole.fr
Asma Siari
• As a Technology & Market Analyst in the Medical Technologies (MedTech) business unit at Yole Développement (Yole), Asma Siari is involved in the
development of technology & market reports as well as the production of custom consulting projects. After a Master’s degree in Biotechnologies,
Diagnostic Therapeutics & Management, Asma serves as Research Assistant at the Moores Cancer Center (San Diego, CA). She is a coauthor in two
scientific publications published in the Molecular Cancer Research Journal. In addition to her mission at Yole, Asma is graduated with an Advanced
Master’s degree in International Strategy & Marketing BtoB (EM Lyon Business School, France).
• Email: siari@yole.fr
4. 4
REPORT CONTENT
• Explain what liquid biopsy is, why it is used, and the characteristics of each biomarker (ctDNA,
CTC, exosomes)
• Market analysis of M&A, collaborations, fundraisings, and business models
• Technical and biological requirements, product examples, key players, market share, and technology
trends
• Market overview and forecasts at service and device levels, for ctDNA and CTC applications
• Overview of the market’s main players and the technologies involved, including company profiles
• Focus on downstream analysis and identification of the main technologies used for liquid biopsy
• Supply chain analysis
5. 5
WHO SHOULD BE INTERESTED BY THIS REPORT?
o Biotechnology & Pharmaceutical Companies:
• To understand what is the state of the art of liquid
biopsy technologies
• To identify the different players across the supply chain
• To understand behavior evolution and identify new
business models
• To identify competitors and targets for collaborations
or M&A
o Equipment & Material suppliers:
• To understand the technical evolution of ctDNA, CTC
and exosome solutions involved in the detection and
isolation process
• To identify business opportunities and prospects
o R&D players:
• To understand challenges linked to the use of liquid
biopsy systems
• Address the right market with the right technology
o Industrial & service companies:
• Grasp which solutions could bring operational benefits
o Medical devices outsourcing companies:
• To have a broad overview of all applications & markets
• To identify new Liquid biopsy markets
• To monitor and benchmark potential competitors
• To understand behaviors evolution
o Microfluidic foundries and device makers:
• Grasp technical requirements, depending on the
application
• Target business opportunities and prospects
o Financial & Strategic investors:
• To understand the potential of liquid biopsy in the
consumer and healthcare industries
• To know the latest moves within the industry
• To get a list of players and their activities in the field of
diagnostic using liquid biopsy
o Healthcare & governmental organizations:
• Evaluate the benefits of using non invasive testing
• Pinpoint relevant companies
6. 6
TABLE OF CONTENTS
• Executive Summary 9
• Introduction 50
• What is liquid biopsy?
• What can we learn from Liquid Biopsy?
• Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA)
• Report scope
• Liquid Biopsy Market Analysis 64
• Applications and drivers
• Cancer prevalence
• Liquid biopsy ecosystem
• Mergers and acquisitions/collaborations
• Fundraising analysis
• Market data and forecasts 2017 - 2023
• Business models
• Regulations status
• Roadmaps
• Circulating Tumor DNA and Exosomes 89
• Introduction to ctDNA and exosome technologies in liquid biopsy
• Workflow for detection of ctDNA and exosomes in cancer patients
• Main players and market share
• Market data and forecasts 2017 – 2023
• Supply chain analysis
• Company profiles
• Circulating Tumor Cells 132
• Introduction to CTCs
• CTCs - analysis workflows in liquid biopsy
• CTCs - enrichments and isolation methods
• Workflow coverage for the main CTC players
• Main players and players map
• Market data and forecasts 2017 – 2023
• Supply chain analysis
• Company profiles
• Downstream Analysis 184
• Overview of analytical approaches for liquid biopsy
• Main technologies and requirements
• Focus on next-generation sequencing: main players and applications
• Focus on polymerase chain reaction and beaming technology - main players
and applications
• Company profiles
• General Conclusions 208
7. 7
LIQUID BIOPSY
Definition
The
advantages of
liquid biopsy
• Liquid biopsy hold the hopes of answering the needs for a
less invasive procedure that could give a better picture of
the cancer diagnosis, treatment or recurrence.
• Tissue biopsy are more invasive hence only provide a
snapshot of the disease as it can’t be easily repeated.
• But maybe the greatest limitation to tissue based biopsy
techniques is that sampling of a single tumor may not
capture all of the mutations present.
• Liquid biopsy allows for real-time, serial and longitudinal
monitoring during cancer therapy.
• It also provides a more comprehensive view of the tumor’s
biomarkers. http://liquid-biopsy.gene-quantification.info/
8. 8
LIQUID BIOPSY
What is analyzed?
Analyses of
circulating tumor
cells (CTC),
circulating tumor
DNA (ctDNA),
and tumor-
derived
extracellular
vesicles can
enable tumor
characterization
by minimally
invasive means
Liquid biopsy
Circulating tumor cells (CTCs) Circulating tumor DNA (ctDNA)
Extracellular vesicles (EVs)
9. 9
LIQUID BIOPSY
Liquid biopsy in the care pathway of cancer patients
• According to the National Institutes of Health’s clinical trials database, clinicaltrials.gov, over 250 trials are currently studying the
use of liquid biopsies in cancer detection, identification, or treatment in the USA only.
• Liquid biopsy can be used at various stage in the care pathway of cancer patients from screening, to monitoring of treatments
and understanding drug resistance mechanisms.
• What’s needed to make a difference in patients’ lives is clinical evidence of sensitivity, selectivity, and efficacy.
Screening for
Early Detection
Profiling
Cancer
Developing
Personalized
Treatment
Monitoring
Treatment
Assessing
Possible
Recurrence
Detect cancer earlier to
start treatment earlier
Identify people at risk for
developing cancer
Understand molecular
mechanisms associated
with this patient
Choose and develop a
tailored treatment
Monitor treatment’s
efficiency along with
drug resistance
Screening for disease
recurrence
10. 10
LIQUID BIOPSY
Scope of the report
• We decided to focus our report on cancer liquid biopsy as the other applications are quite different in term of
market dynamics and players.
• We focused our reports on ctDNA, CTCs and exosomes analysis as protein analysis for liquid biopsy are more
in a research stage today.
• In our market analysis we focused on companies developing liquid biopsy kits, instruments and service.
In the report Not in the report
Applications Cancer
Others (noninvasive prenatal testing,
etc.)
Biomarkers ctDNA, CTCs, exosomes Proteins
Market analysis
Companies developing liquid biopsy kits,
instruments and services
17. Cancer is a rising concern in modern society.
Numerous drivers contribute to the increase of
cancer cases, such as ageing of the population,
lifestyle, and environment. According to the World
Health Organization, cancer is responsible for one
in six deaths worldwide, and one in two people are
likely to develop cancer in their lifetime. Cancer
cells are cells whose genes have mutated; in order
to understand each cancer’s mechanisms and
determine the appropriate treatment, these tumors
require analysis. Traditional biopsy methods involve
obtaining a piece of the tumor through invasive
surgery. However, these procedures are expensive
and exhausting for the patient, and cannot be
reproduced regularly in order to monitor a cancer’s
evolution and treatment efficiency over time.
However, it is now possible to avoid such invasive
procedures thanks to a “liquid biopsy”. Indeed, it
is possible to collect a simple blood draw in which
relevant biomarkers can provide useful information
about the patient’s cancer. In particular, a number
of companies are developing technologies to
collect, isolate, and analyze circulating tumor
DNA (ctDNA: DNA molecules shed by cancerous
cells) and circulating tumor cells (CTCs: tumor
cells shed from the original tumor) that spread
into the bloodstream. Thanks to these tools, it is
possible to not only diagnose cancer uninvasively,
but also to understand the molecular mechanisms
associated with each patient, choose and develop
a tailored treatment, monitor the treatment’s
efficiency (along with drug resistance), and screen
for disease recurrence. Some companies are even
working on screening for early detection, although
this is a more long-term application.
Liquid biopsy thus has the potential to assist
at every stage of cancer care, saving lives and
cutting healthcare costs. The opportunity is huge,
and the associated market is already large and
growing extremely fast. According to this Yole
Développement report, the liquid biopsy market
will grow from $1.7B in 2017 at a CAGR2017-2023
of 29%, reaching $7.8B by 2023. This includes
hardware (systems and devices) and reagent kit
sales, along with service revenue, for CTC and
ctDNA applications.
LIQUID BIOPSY: FROM ISOLATION TO DOWNSTREAM
APPLICATIONS 2018
Market & Technology report - June 2018
LIQUID BIOPSY: A POWERFUL EMERGING TOOL FOR CANCER CARE, AND
A HUGE BUSINESS OPPORTUNITY
How will liquid biopsy change cancer care?
KEY FEATURES
• Introduction to liquid biopsy
testing, definitions, and why it is
used
• Market analysis of mergers and
acquisitions, collaborations,
fundraisings and business models
• Technical and biological
requirements, product examples,
key players, market share, and
technology trends
• Market overview and forecasts at
both service and device levels, for
circulating tumor DNA (ctDNA:
DNA molecules shed by cancerous
cells) and for circulating tumor cells
(CTCs: tumor cells shed from the
original tumor) applications
• Overview of the market’s main
players and the technologies
involved, including company
profiles
• Focus on downstream analysis
and identification of the main
technologies used for liquid biopsy
• Supply chain analysis
(Yole Développement, June 2018)
Liquid biopsy: a game-changer in cancer care
WHY LIQUID BIOPSY?
WHAT IS ANALYZED IN LIQUID
BIOPSY?
WHAT QUESTIONS COULD
LIQUID BIOPSY ANSWER?
vs
Circulating Tumor
Cells (CTCs)
Exosomes
Circulating Tumor
DNA(ctDNA)
Early detection
and diagnosis
Personalized
treatment
Monitoring
treatment
Assessing
recurrence
Standard
Biopsy
Liquid Biopsy
Invasive Minimally invasive
Localized sampling
of tissue
Comprehensive
tissue profile
Time intensive Quick
Some associated
pain and risk
for the patient
Minimal pain
and risk for
the patient
AN IMPRESSIVE RANGE OF COMPANIES AND BUSINESS MODELS
Studying mutations in cancer cells’ DNA is not
an easy task, and requires many different tools
and skills. From the enrichment and analysis
of biomarkers to the bioinformatics analysis of
mutation profiles, the path is long and many players
are involved. This report confirms the role of each
player at each level of the supply chain, explains
who is specialized in which step, and details where
the value lies and how the development of liquid
biopsy is boosting downstream analysis equipment
markets like sequencing and digital PCR. The
difference and complementarity of ctDNA and
CTCs is also described, and Yole Développement’s
analysts explain why CTC has yet to attract
significant funding, and how the situation may now
change thanks to recent findings.
Indeed, ctDNA companies have raised more than
$3.7B since 2010, while CTC companies have only
raised around $280M. In terms of revenue, the split
18. LIQUID BIOPSY: FROM ISOLATION TO DOWNSTREAM APPLICATIONS 2018
TECHNOLOGICAL BREAKTHROUGHS ARE DRIVEN BY MICROFLUIDIC TECHNOLOGY
Many steps in the liquid biopsy workflow have been
made possible thanks to microfluidic technologies.
From isolation to downstream analysis, microfluidic
devices are involved everywhere. A major part of CTC
enrichment and isolation systems relies on microfluidic
devices that enable separation of CTCs from other
blood cells, using their physical properties such as
size, shape, deformability, and dielectric properties.
Important companies such as Angle plc, Celsee,
Clearbridge Biomedics, and Vortex Biosciences rely
on microfluidics. These microfluidic methods work
for a wide range of cells and enable high throughput
capture at a low cost. Moreover, downstream analysis
solutions also rely on microfluidic technologies in
numerous cases: DNA sequencers from Illumina, Ion
Torrent, and others use microfluidic flow cells, and
other technologies like droplet digital PCR from Bio-
Rad, Stilla Technologies, and RainDance (acquired by
Bio-Rad) are also microfluidic technologies.
All of these state-of-the-art technologies are enabled
by innovative microfluidic hardware and allow more
complex analyses to be performed, thus contributing to
concrete improvements in cancer care. In this report,
Yole Développement focuses on these microfluidic
technologiesateveryleveloftheliquidbiopsy workflow.
is also unbalanced in favor of ctDNA companies. This
is primarily due to business models: most ctDNA
companies offer testing services in their Clinical
Laboratory Improvement Amendments (CLIA)
labs, performing tests developed in-house which do
not require Food and Drug Administration (FDA)
clearance. Moreover, DNA is easier to transport and
store than live cells, which is another advantage for
ctDNA. On the contrary, most CTC companies are
developing instruments that are directly sold to end-
users, along with the associated consumables.
However, most of these instruments for CTC
isolation are still for research use only because the
FDA requires more evidence of the benefits derived
from analyzing CTCs in patients’ survival rate, before
approving them for clinical use. This explains, at least
partially, why CTC companies are lagging behind in
terms of revenue. Thankfully, this situation may soon
change thanks to advances in technology and to the
increasing number of published works proving the
clinical value of CTC analysis: in fact, a complete live cell
can carry much more information than a DNA strand.
Immuno-enrichment
methods (antibody labeling)
Physical properties
Positive and/or negative
immuno-enrichment
Size, shape, deformability
(filtration, inertial focusing…)
Dielectric properties
Enrichment-free
Direct
imaging
Immunomagnetic separation,
fluorescence detection
Usually microfluidic chip /
microstructures / microfilters
Dielectrophoresis
(DEP) based CTC
enrichment
Fluorescence staining of glass
slides
Centrifugation + fluorescence
staining of glass slides
Enrichment-free / density-
based separation
Non-exhaustive list of companies, * CTC: circulating tumor cell
Density-based enrichment
Density gradient
centrifugation + fluorescence
staining of glass slides
Liquid biopsy market ecosystem for 2017
(Yole Développement, June 2018)
Indirect liquid
biopsy market:
downstream
analysis companies
ctDNA**
andexosomes
companies
CTC* companies
Liquid
biopsy
market
* CTC: circulating tumor cell
** ctDNA: circulating tumor DNA
Non-exhaustive list of companies
Liquid biopsy market: technologies for CTC* workflows
(Yole Développement, June 2018)
19. MARKET TECHNOLOGY REPORT
COMPANIES CITED IN THE REPORT (non exhaustive list)
Abbott, AdnaGen, Agilent Technologies, Amazon, Amgen, Angle, ApoCell, Assurex Health,
AstraZeneca, Axon Dx, BD, Beckman Coulter, BGI, Biocartis, Biocept, Biodesix, BioFluidica, Bio-Rad,
Bioview, Bristol Myers Squibb, Cambridge Consultants, CellMax Life, CellSearch, Celsee, Circulogix,
Cirina, Clearbridge BioMedics, Clinical Genomics, Cogent, Creativ MicroTech, Cynvenio, CytoLumina,
CytoTrack, DiaDx, Diagnologix, Epic Sciences, Epigenomics, Exact Sciences, ExosomeDx, FivePrime,
Fluxion, Foundation Medicine, Freenome, GE Healthcare, Genapsys, Gendia, Genomic Health, Gilupi,
GnuBio, Grail, Greiner Bio-One, Guardant Health, HP, IBM Watson, iCellate, IKOTECH, Illumina,
IncellDx, Inivata, Janssen Pharmaceuticals, Johnson Johnson, Life Technologies, LifeArc, Livzon,
Menarini Silicon Biosystems, Merck, Microsoft, Mikro Biyosistemler, Miltenyi Biotec, Myriad, Nabsys,
Nanostring, Natera, Noblegen, Novartis, Oncocyte, Oxford Nanopore, Pacific Biosciences, Pathway
Genomics, Personal Genome Diagnostics, Pfizer, Predicine, Qiagen, RareCells, Roche, SBI, ScreenCell,
Sigma Aldrich, Simfo, Sividon Diagnostics, SRI Biosciences, StemCell Technologies, Stratec, Streck,
Sysmex, TeloVision, Thermo Fisher, Thermo Fisher Scientific, ThinXXS, Trovagene, Veracyte, Vitatex,
Vortex Biosciences, Zomedica,… and many more
Executive summary 9
Introduction 50
What is liquid biopsy?
What can we learn from liquid biopsy?
Circulating Tumor Cells (CTCs) and circulating
tumor DNA (ctDNA)
Scope of the report
Liquid biopsy market analysis 64
Applications and drivers
Cancer prevalence
Liquid biopsy ecosystem
Mergers and acquisitions/Collaborations
Fundraising analysis
Market data and forecasts 2017-2023
Business models
Regulations status
Roadmaps
Circulating tumor DNA and exosomes 89
Introduction to ctDNA and exosomes
technologies in liquid biopsy
Workflow for detection of ctDNA and
exosomes in cancer patients
Main players and market share
Market data and forecasts 2017–2023
Supply chain analysis
Company profiles
Circulating tumor cell 132
Overview of analytical approaches for liquid
biopsy
Main technologies and requirements
Focus on next generation sequencing : main
players and applications
Focus on polymerase chain reaction and
beaming technology: main players and
applications
Company profiles
Downstream analysis 184
Introduction to CTCs
CTCs analysis workflows in liquid biopsy
CTCs enrichments and isolation methods
Workflow coverage for the main CTCs players
Main players and players map
Market data and forecasts 2017–2023
Supply chain analysis
Company profiles
General conclusions 208
TABLE OF CONTENTS (complete content on i-Micronews.com)
OBJECTIVES OF THE REPORT
• Explain what liquid biopsy is, why it is used, and the characteristics of each biomarker (ctDNA,
CTC, exosomes)
• Show what constitutes “state-of-the-art” is today and what is expected for tomorrow, and
understand the positive and negative impacts on the adoption of liquid biopsy for clinical use
• Provide a players overview at each supply chain level, from enrichment and isolation to
downstream analysis, for CTC and ctDNA applications
• Provide a list and analysis of fundraisings and MA
• Provide an analysis of the business models used in the liquid biopsy field
RELATED REPORT
Benefit from our Bundle Annual Subscription offers and access our analyses at the best available
price and with great advantages
• Point-of-Need Testing 2018
• Organs-on-Chips 2017
Find all our reports on
www.i-micronews.com
AUTHORS
Sébastien Clerc worksasaTechnologies
Market Analyst, Microfluidics Medical
Technologies. Sébastien authored a
collection of market and technology reports
dedicated to topics such as microfluidics,
point-of-care and more. In parallel, he is
daily involved in custom projects. Thanks
to its technology market expertise,
Sébastien has spoken in more than 10
industry conferences worldwide over the
last 2 years. Sébastien Clerc is graduated
from Grenoble Institute of Technology
(Grenoble INP - Grenoble, France) with a
Master degree in Biomedical Technologies.
Then he completed his cursus with a Master
degree in Innovation and Technology
Management in the same institute.
As a Technology Market Analyst,
Biotechnologies Molecular Innovations,
Asma Siari is involved in the development
of technology market reports as well as
custom consulting projects. After a Master’s
degree in Biotechnologies, Diagnostic
Therapeutics Management, Asma served
as Research Assistant at the Moores Cancer
Center (San Diego, CA). She is a coauthor
in two scientific publications. Asma Siari
is graduated with an Advanced Master’s
degree in International Strategy Marketing
BtoB from EM Lyon Business School (Lyon,
France).
As a Technology Market Analyst,
Medical Imaging Biophotonics, Dr.
Marjorie Villien is a daily contributor
to the development of medical technologies
activities with a dedicated collection of
market technology reports as well as
custom consulting projects. After spending
two years at Harvard, Marjorie served
as a research scientist at INSERM in the
field of medical imaging. She has spoken
in numerous international conferences and
has authored or co-authored 11 papers and
1 patent. Marjorie Villien is graduated from
Grenoble INP (Grenoble, France) and holds
a PhD in physics medical imaging.
Dr. Marjorie Villien, Asma Siari and Sébastien Clerc,
all part of the Life Sciences Healthcare division at
Yole Développement co-authored the Liquid Biopsy:
From Isolation To Downstream Applications report:
Find more
details about
this report here:
20. ORDER FORM
Liquid Biopsy: From Isolation to Downstream Applications 2018
SHIPPING CONTACT
First Name:
Email:
Last Name:
Phone:
PAYMENT
BY CREDIT CARD
Visa Mastercard Amex
Name of the Card Holder:
Credit Card Number:
Card Verification
Value (3 digits except AMEX: 4 digits):
Expiration date:
BY BANK TRANSFER
BANK INFO: HSBC, 1 place de la Bourse,
F-69002 Lyon, France,
Bank code: 30056, Branch code: 00170
Account No: 0170 200 1565 87,
SWIFT or BIC code: CCFRFRPP,
IBAN: FR76 3005 6001 7001 7020 0156 587
RETURN ORDER BY
• FAX: +33 (0)472 83 01 83
• MAIL: YOLE DÉVELOPPEMENT, Le Quartz,
75 Cours Emile Zola, 69100 Villeurbanne/Lyon - France
SALES CONTACTS
• Western US Canada - Steve Laferriere:
+ 1 310 600-8267 – laferriere@yole.fr
• Eastern US Canada - Troy Blanchette:
+1 704 859 0453 – troy.blanchette@yole.fr
• Europe RoW - Lizzie Levenez:
+ 49 15 123 544 182 – levenez@yole.fr
• Japan Rest of Asia - Takashi Onozawa:
+81 34405-9204– onozawa@yole.fr
• Greater China - Mavis Wang:
+886 979 336 809 – wang@yole.fr
• Specific inquiries: +33 472 830 180 – info@yole.fr
(1)
Our Terms and Conditions of Sale are available at
www.yole.fr/Terms_and_Conditions_of_Sale.aspx
The present document is valid 24 months after its publishing date:
June 7, 2018
/
ABOUT YOLE DEVELOPPEMENT
BILL TO
Name (Mr/Ms/Dr/Pr):
Job Title:
Company:
Address:
City:
State:
Postcode/Zip:
Country*:
*VAT ID Number for EU members:
Tel:
Email:
Date:
PRODUCT ORDER - Ref YD18020
Please enter my order for above named report:
One user license*: Euro 5,990
Multi user license: Euro 6,490
- The report will be ready for delivery from June 18, 2018
- For price in dollars, please use the day’s exchange rate. All reports are
delivered electronically at payment reception. For French customers,
add 20% for VAT
I hereby accept Yole Développement’s Terms and Conditions of Sale(1)
Signature:
*One user license means only one person at the company can use the report.
Founded in 1998, Yole Développement has grown to become a group of companies providing marketing, technology and strategy consulting, media and
corporate finance services, reverse engineering and reverse costing services and well as IP and patent analysis. With a strong focus on emerging applications
using silicon and/or micro manufacturing, the Yole group of companies has expanded to include more than 80 collaborators worldwide covering MEMS and image
sensors, Compound Semiconductors, RF Electronics, Solid-state lighting, Displays, Software, Optoelectronics, Microfluidics Medical, Advanced Packaging,
Manufacturing, Nanomaterials, Power Electronics and Batteries Energy Management.
The “More than Moore” market research, technology and strategy consulting company Yole Développement, along with its partners System Plus Consulting,
PISEO and KnowMade, support industrial companies, investors and RD organizations worldwide to help them understand markets and follow technology
trends to grow their business.
CONSULTING AND ANALYSIS
• Market data research, marketing analysis
• Technology analysis
• Strategy consulting
• Reverse engineering costing
• Patent analysis
• Design and characterization of innovative optical systems
• Financial services (due diligence, MA with our partner)
More information on www.yole.fr
MEDIA EVENTS
• i-Micronews.com website related @Micronews e-newsletter
• Communication webcast services
• Events: TechDays, forums…
More information on www.i-Micronews.com
REPORTS
• Market technology reports
• Patent investigation and patent infringement risk analysis
• Teardowns reverse costing analysis
• Cost simulation tool
More information on www.i-micronews.com/reports
CONTACTS
For more information about :
• Consulting Financial Services: Jean-Christophe Eloy (eloy@yole.fr)
• Reports: David Jourdan (jourdan@yole.fr) Yole Group of Companies
• Press Relations Corporate Communication: Sandrine Leroy (leroy@yole.fr)